MyMD Pharmaceuticals, Inc. MYMD Stock (” MyMD” or “the Firm”), a scientific phase pharmaceutical company devoted to extending healthy lifespan, today revealed that the initial individual has been registered in the Company’s Phase 2 scientific trial of lead candidate MYMD-1, an oral immune regulatory authority medication, as a treatment for delaying aging and broadening healthy life expectancy.
The key endpoint for the Stage 2 double-blind, placebo-controlled professional test is to attain a reduction in the circulating degrees of (TNF-α), growth necrosis variable receptor I (TNFRI) and IL-6. TNF-α and IL-6 are the healthy proteins in the body that create inflammation and assist trigger the procedure of aging. The additional procedures of the test will be the safety, tolerability, and also pharmacokinetics in this populace of individuals.
” In a Stage 1 medical test of MYMD-1, we showed the drug’s statistically significant efficacy in minimizing degrees of TNF-α, a principal in creating pathological aging, in the blood. The FDA has accepted TNF-α decrease as the key endpoint for our Phase 2 research study, which our company believe positions us well for an effective Stage 2 end result,” said Chris Chapman, M.D., Head Of State, Supervisor and Principal Medical Policeman of MyMD. “The initiation of client registration in this research advances our mission to slow down the aging process, prevent loss of muscle cells in aging, restriction frailty, and also prolong healthy and balanced life-span.”
MyMD has actually stated that there are no FDA-approved medicines for dealing with aging conditions and prolonging healthy life-span humans, a market expected to be a minimum of $600 billion by 20251 according to a major investment bank. TNF-α blockers are the most prescribed drugs by profits, an international market of approximately $40 billion each year,2 and also, according to Nature Aging journal,3 a downturn in maturing that would raise life expectancy by one year is worth $38 trillion and by 10 years deserves $367 trillion.
In addition to aging, MYMD-1’s distinct activity in regulating the body immune system and treating persistent inflammation is being created for the treatment of autoimmune disease, consisting of rheumatoid arthritis (RA), multiple sclerosis (MS), diabetes mellitus, as well as inflammatory digestive tract disease.
” We mean to begin composing protocols for a Phase 2 pilot study of MYMD-1 for rheumatoid joint inflammation early this year,” Dr. Chapman kept in mind. “The climbing occurrence of rheumatoid arthritis and other autoimmune as well as inflammatory diseases are driving need for TNF inhibitors like MYMD-1, as well as our company believe our by mouth provided drug with extremely low poisoning would certainly be disruptive to the $60 billion market for RA if accepted by the FDA for this indicator.”
Rheumatoid joint inflammation impacts roughly 40 million people worldwide.4.
Originally established for autoimmune illness, MYMD-1’s key purpose is to reduce the aging process, avoid sarcopenia and also frailty, and extend healthy and balanced life expectancy. Since it can cross the blood-brain barrier and also get to the central nerves (CNS), MYMD-1 is also placed to be a feasible therapy for brain-related problems. Its device of action and also efficacy in diseases including several sclerosis (MS) as well as thyroiditis have been researched with collaborations with numerous academic organizations. MYMD-1 is additionally showing guarantee in pre-clinical research studies as a possible treatment for post- COVID-19 problems and as an anti-fibrotic and also anti-proliferation healing.
MYMD-1 has actually revealed efficiency in pre-clinical research studies in managing the body immune system by executing as a selective inhibitor of growth death factor-alpha (TNF-α), a driver of chronic swelling. Unlike various other therapies, MYMD-1 has been shown in these pre-clinical studies to selectively block TNF-α when it becomes overactivated in autoimmune conditions and also cytokine storms, however not obstruct it from doing its normal job of being an initial -responder to any type of regular kind of modest infection. MYMD-1’s ease of oral dosing is an additional differentiator contrasted to currently offered TNF-α blockers, all of which require distribution by injection or infusion. No accepted TNF inhibitor has actually ever before been dosed by mouth. Additionally, the medicine is not immunosuppressive and also has actually not been revealed to create the severe side effects common with traditional therapies that treat inflammation.
Concerning MyMD Pharmaceuticals, Inc
. MyMD Pharmaceuticals, Inc. (Nasdaq: MYMD), a clinical stage pharmaceutical firm dedicated to expanding healthy life expectancy, is focused on establishing two novel restorative platforms that treat the reasons for condition as opposed to only resolving the signs and symptoms. MYMD-1 is a drug platform based upon a professional phase little particle that controls the body immune system to manage TNF-α, which drives chronic inflammation, as well as other pro-inflammatory cell signaling cytokines. MYMD-1 is being developed to delay aging, boost long life, and also deal with autoimmune conditions and COVID-19- connected clinical depression. The Business’s second medication platform, Supera-CBD, is being created to treat persistent discomfort, dependency as well as epilepsy. Supera-CBD is an unique synthetic derivative of cannabidiol (CBD) and also is being established to deal with and also surpass the quickly growing CBD market, which includes both FDA authorized medicines as well as CBD items not currently regulated as medications. For additional information, go to www.mymd.com.